lawpalyer logo
in判決書

臺灣雲林地方法院104年度公字第1號

關鍵資訊

  • 裁判案由
    損害賠償
  • 案件類型
    民事
  • 審判法院
    臺灣雲林地方法院
  • 裁判日期
    113 年 11 月 29 日

  • 當事人
    張淑芬丁願忠王芳

1041 滿 貿 歿 歿 113 9 13     255 1 255 1 105 437 歿106 1012104 11 3 105 3 22111 141 249 2 1 561 1 1151使828 3 使821 831 828 3 104 3 106 8 13 2 112 9 21 431 44 7 168 175 107 1216 155 185 113 8 1214 149 153189 191 267 269 305 307 249 1 3 111 118 4 07 425 419 170 168 172 175 1 113 8 1411 9 131 8 149 9 133 147 421 431 5% 885 Group 1 Group 2AGroup 2B(IARC)(US.EPA)調西100 3.47E-053.47102 3.62E-053.62103 2.16E-052.16104 1.64E-051.641 ×10-051 ×10-6) 使 1 1   2 1,3 1 3 1 4 1 5 1     6 2A       7 1,2- 2B 8 2B 9 2B 10 2B 11 2A 12 2B 13 2B       14 2B 15 1,3- 2B   16 2A 17 2A 18 2A         19 1 20 2B 21 2B 22 PAHs 1 23 1   24 1         25 2A   26 1   27 1           28 2B       29 2B   30 - 2B 31 1 32 2B   33 1,2- 2A   34 2B 35 1,1,2,2- 2B   36 2B   37 2A   38 1     39 1 107 1 40110 1 150%IARC 西101 5 103 6 49.6-193.6ppb(max)1.77-3.76ppb()(23247) 104 -2 (21280)3-150 107.957 / 105.824/98.02%101.871/81.366/79.87%88.311/ 44.238/ 50.09%72.175/42.032 / 58.24%64471.765 / 266.843/101.463/49.654/ (21282) -2 ISCST3 64 20× 2030× 302011~201552011201220132015 西(22353) 西 97102 調()尿西(1139212-21) )1,3- 1,2-PAHs( )(12378222324)西 尿22232410西尿1-OHP 西西PAHs (1139222-24)Google         A01-A02-A9- 西 A03- A04-B01-B08- A05-A06-A13- A14-B05- A07-A08-B06- A10-A11-A12-A17-A18-B04- A16- A19-B03-B07- A15- B02- B09- IARC315 316 Gr oup1(carcinogenic to humans Group2A(probably carcin-ogenic to humansGroup2B possibly carcinogenic to humans)Group3(not classifiable as to its carci-nogenicity to humans )Group 4 (probably not carcinogenic to humans) RCA 107 267 110 50Group1Group2A Group2B IARCUS.EPA) Group 1 Group 2AGroup 2B11392 34-69 (209135-145) 97102 調調調1139272-78 (1×10-6)1061021031041 0-6 97-101356358西103-115100 3.47E-05 3.47102 3.62E-053.621032.16E-052.16104 1.64E-051.64西 西西Group1Group 2A Group 2BIARCUS.EPA97102 調100 3.47E-05103.47102 3.62E-05103.62103 2.16E-05102.161041.64E-05(101.64) 184 1 2 185 1 191 3 192 1 2 193 1 194 195 1 185 1 9 139 209 ( ) 244 1 2 266 1 1 3 尿 1 ( ) 1-A1-B 5 RCA 5 1-A 1-B 2012116 1 1 IARC111 Dose ResponseAssessment (NRC1983) RfDreference doseRfCreference concentration slope factor) : No-observed-adverse effect level, NOAEL Lowest-observed-adverse effect level, LOAEL ()調()(Polycyclic Aromatic Hydrocarbons,PAHs)()綿 (toxicokinetics)(physiological based pharmacokinetics,PBPK) ( ) 5 1-A1-B西5 101 102 5 C52 1-A1-B 100 101 8 1 稿731 100 沿 西西10SO3.14 5.19ppbSO3 0ppbSO250ppb10941 933.36ppb 140ppbS O75ppb30ppb西 西SO 75ppb使 西西100SO西 9299 104 10464 107.957/105.824/98.02%101.871/88.311/72.175/-298VOCs2-69 C52 : 199920013200820103 西0.430.380.320.390.420.360.290.37使西 西 107 1 94107 26.73%35.88%西32.01%37.77%西1081102 21.135.021.038.523.839.221.935.1 調西調104 調107調調調 107西108調調23調2 11109 731090047697調調 調5 1041.27×l0-5西1.64×l0-56.39×l06-47-4( 109 2 調98104 ) 1841 104122411 5 837 (Best Available Control Technology, BACT)877,5511,26116.7 24 95(5) 西1031.39ppbc(33)97()(34) 157 1 1 2 3 (104 9 9 133) Cadmium RCA 107 134 971 2 RCA () 廿 9193RCA110 9193 RCA RCA 81 9394110RCA RCA RCA 95CHEMOSPHERE ( 148150233236)(3) 調 ()調 PCDD /PCDF(251 2603 01137) 1913 RCA 5 ? ( 7 ) 157 942 ()(122) 10-6~10-4 ()() (cancer risk) [10-6~10-4(101)102324稿調10-610-6~10-4(112)10-6~10-4 10-610-4 1913 ()(123) 10-610-4 10-610-4(1112 2232) 2.76x10-51003.74 x 10-5 102 1.47x10-5103 1.27x10-5 104西3.47 x10-5(100)3.62x 10-5102 2.16x10-5103 1.64 x 10-5(104) 使 10-610-4191 3 40% 50%10-610-410478.07381.27x10-5西1.64x10-5 8040%(124)39.5%( 125)50%(126) 40%50% 10-610-4() 40%()40%50%104 78.07381.27x10-5西1.64x10-540%~50% 10-610-4(78.07)36524 10-6 Risk=LADDtotal× SFRisk=C× Unit RiskLADDtotalmg/kg/day78.07) (LADD) 102-104 78.07 (year) 78.07365 1041.27x10-5西1.64x10-59410 (10-6)(10-4)(112 )Where the cumulative carcinogenic site risk to an individual basedonreasonable maximum exposure for both current and future landuse is less than 10-4 and the non-carcinogenic hazard quotient is lessthan 1, action generally is notwarranted unless there are adverse environmental impacts A 10-4risk level corresponds to the upper-end of EPAs generally acceptable riskrange of 10-6 to 10-4 as discussed in the National Contingency Plan(NCP), 40 CFR 300.430.(使10-4110-410-6 10-4(40 CFR 300.430.)12710-610-410-6 10-610-4 2132 10-510-6 832197774 使使調使使調 調使774 774 110 1 210 107 1 10381 1057 191063141051019 0000000000106 1 333 00000000 113 10220 使 102 5 103610662 109 1110662 212352542 10662 12.422923167.52312934110 6 7.88.6178181 1 0099 4134100 .08.09104199.07.283111100 10111717? 645 3 5 173020108 20158 5 1691998(16)17182015319201082015855 5645448(6)380107336(23)141,960,59010353 17245 84 18 72 2011512101 2 20115122335 18-19 162 223 231 2 24435 1 7 20161730 8790 8 88100 13 9 88909395 96979899100 使 1-A 1-B RCA RCA RCA 宿使( )RCA 1,300 3,199 ()尿 5 5 500 5 94104 94104 西102694104 10 TEDS8.1 1 )99 39.66%60.85%( ) 30.02%PM2.5 21.27%()57.92%22.86% (104991010412243)( 1832) (1214)(911) (1516) 6106861115 8 200997沿1 324 10-15325 5 VOCsPM2.5VOCsPM2.5 PM2.5 PM2.5 2.8 PM2.5 99TEDS8.1 1 39.66%12.64%8.55% 60.85%30.02%PM2.5 21.27%13.94%11.63%11.08%57.92%( 22.86%2 104 9 28 3 104 109 E-BIKEE -BUS 使 (PM2.5) 8 ( 1214)(9 11)(1516)9596 183218PM2.5 西 IARC"Hazard"(An agent is capable of causing cancer undersome circumstances,technically calledHazard) (Risk) does not measure the li kelihood that cancer will occur as a result of exposure to the agent,technically calledRisk) ( 8 38Causation 38) 202 2495(119 )24 104 調調調2 1 1 109 7 3 1090047697調調108 調5 811 0 西20032007476.30000-0000240.7 278.10000-0000105(25) 西94西138 使197 1 492652使982377102 8 1310208894 184 1 277 5 5 277 使調99408 107 3 107 267 使調 A011 A19 4 B03 B04 B06 B07 B08 B01 1 B01 2 B01 B02 1 B02 2 B02 西 17213739434769738991109 1 11 161163175177197199207209233 2352 55259275279295297 305311341 347 355 357 367 369373377 387 391 399 401 405 409 413 417 445 449 453455143145 161 171 18 88西19995 94西20051,3-1,2-1,3-2-- 1,2-1,1,2,2-IARCGroup1carcinogenic to humans )Group2Aprobably carcinogenicto humans )Group2B possiblycarcinogenic to humans )IARC145 175 281 328330 332339 342 346 349 352 353 356 358 362363 374 375 378 380 384 385394395 398 399 402 14151820212425282932343840414647545558596465747575 5 123 97沿1 98101 沿102 沿323 325 3765 IARC1 1,3-253 293 1 risk characterization 5 調20002000; 200020002000104 53 94107 317 345 26.73% 35.88%西32.01%37.77%西1081102 21.135.021.038.523.839.221.935.1347 西C52 199920013 200820103 西0.430.380.320.390.420.360.290.375 3 11 315 西5 5 5 7 31100 沿 西西10SO 3.145.19ppb SO 30ppb SO 250ppb10941 933.36ppb 140ppbSO 75ppb 30ppb 西西SO 75ppb 使西西100 SO 西 9299 101 8 1 稿305 西5 5 5 184 1 2 185 191 3 192 195 5 851 78         113    11    29      廿         113    11    29                                       104 1                 A01-1 23,800   424,500 500,000 1,603,928   2,552,228 A01-2         445,480   945,480 A02-1         301,013   801,013 A02-2             500,000 A02-3               A02-4               A02-5 227,591           727,591 A03-1 50,077       1,244,762   1,794,839 A03-2             500,000 A03-3         169,971   669,971 A04-1         888,034   1,388,034 A04-2 605,927   456,500       1,562,427 A05-1 10,132   27,497   388,216   925,845 A05-2           537,629 A05-3             A05-4             A05-5   27,496       537,628 A05-6 10,131         537,627 A06-1 114   176,000   328,146   1,004,260 A06-2             500,000 A06-3               A06-4               A07-1 4,215       545,203   1,049,418 A07-2         495,612   995,612 A08-1               500,000 A08-2 73,980   60,000       633,980 A08-3             500,000 A09-1         1,000,000     1,000,000 A10-1       500,000     500,000 A10-2 28,932   310,000       838,932 A10-3             500,000 A11-1 295   27,143       527,438 A11-2           A11-3           A11-4           A11-5           A11-6           A11-7 294   27,142       527,436 A12-1 10,224           510,224 A12-2             A12-3 10,223           510,223 A12-4             A12-5             A12-6             A12-7             A13-1 145,022 227,007 178,000 1,000,000     1,550,029 A14-1       500,000 779,154   1,279,154 A14-2             500,000 A14-3               A15-1 10,658 17,351 191,720       719,729 A15-2 10,657 17,350       719,727 A15-3         A16-1       333,334 376,795   710,129 A16-2             333,334 A16-3       333,333     333,333 A16-4               A16-5               A16-6               A17-1 140,688     500,000     640,688 A17-2             500,000 A17-3               A17-4               A18-1 58,220           558,220 A18-2             500,000 A18-3               A18-4               A19-1       356,000 559,122   915,122 A19-2             356,000 A19-3     663,500       1,019,500 A19-4             356,000 B01-1 2,000,000 2,000,000 B01-2 B02-1 20,992 2,000,000     2,020,992 B02-2 B03   38,255     500,000   2,044,366 2,582,621 B04   780     2,000,000     2,000,780 B05     36,000   2,535,028   504,593 3,075,621 B06   44,260     650,000   305,740 1,000,000 B07   737     2,000,000     2,000,737 B08             141,003 2,141,003 B09 37,896   2,237,896                1041 A01 A02 A03 A04 A05 A06 A07 A08   A09   A10 A11 A12 A13 A14 A15 A16 A17 A18 A19 B01 B02 B03 B04 B05 B06 B07 B08 B09